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Abstract
Introduction: The EPaNIC randomized controlled multicentre trial showed that postponing initiation of parenteral
nutrition (PN) in ICU-patients to beyond the first week (Late-PN) enhanced recovery, as compared with Early-PN.
This was mediated by fewer infections, accelerated recovery from organ failure and reduced duration of
hospitalization. Now, the trial’s preplanned cost analysis (N = 4640) from the Belgian healthcare payers’ perspective
is reported.
Methods: Cost data were retrieved from individual patient invoices. Undiscounted total healthcare costs were
calculated for the index hospital stay. A cost tree based on acquisition of new infections and on prolonged length-
of-stay was constructed. Contribution of 8 cost categories to total hospitalization costs was analyzed. The origin of
drug costs was clarified in detail through the Anatomical Therapeutic Chemical (ATC) classification system. The
potential impact of Early-PN on total hospitalization costs in other healthcare systems was explored in a sensitivity
analysis.
Results: ICU-patients developing new infection (24.4%) were responsible for 42.7% of total costs, while ICU-patients
staying beyond one week (24.3%) accounted for 43.3% of total costs. Pharmacy-related costs represented 30% of
total hospitalization costs and were increased by Early-PN (+608.00 EUR/patient, p = 0.01). Notably, costs for ATC-J
(anti-infective agents) (+227.00 EUR/patient, p = 0.02) and ATC-B (comprising PN) (+220.00 EUR/patient, p = 0.006)
drugs were increased by Early-PN. Sensitivity analysis revealed a mean total cost increase of 1,210.00 EUR/patient (p
= 0.02) by Early-PN, when incorporating the full PN costs.
Conclusions: The increased costs by Early-PN were mainly pharmacy-related and explained by higher expenditures
for PN and anti-infective agents. The use of Early-PN in critically ill patients can thus not be recommended for both
clinical (no benefit) and cost-related reasons.
Trial registration: ClinicalTrials.gov NCT00512122.
Introduction
Previous non-conclusive trials investigating clinical
effects of parenteral nutrition (PN) supplementing ent-
eral nutrition (EN) in critically ill patients were small
[1], and studies analyzing the resource use or costs asso-
ciated with such nutritional strategies are scarce [2]. The
Belgian multicenter EPaNIC (Impact of Early Parenteral
Nutrition completing enteral nutrition In Critical illness)
randomized controlled trial (RCT) has shown that with-
holding PN during the first week of critical illness (Late
PN) was clinically superior to early supplementation of
insufficient EN with PN (Early PN) [3]. In this study,
4,640 patients from seven intensive care units (ICUs) in
three departments from two hospitals were randomly
assigned to Early or Late PN. This trial had adequate
statistical power to detect a difference in length of stay
in the ICU and 90-day mortality, which are, respectively,
the primary efficacy and safety endpoints [4-6]. Patients
randomly assigned to the Early-PN group (n = 2,312)
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received intravenous glucose 20% on days 1 and 2, fol-
lowed by PN, which was targeted to ± 100% of the calo-
ric goal via combined EN and PN. When clinicians
predicted that the patient would tolerate sufficient EN
or oral feeds the following day, PN was not initiated.
Patients randomly assigned to the Late-PN group (n =
2,328) received no PN during the first week in the ICU.
In both groups, management of EN was identical and
patients received parenteral trace elements, minerals,
and vitamins early. Late PN proved to be safe as ICU,
hospital, and 90-day mortality and feeding-related com-
plications in the two groups were comparable. More-
over, Late PN reduced the incidence of new infections
in the ICU, shortened the duration of organ support,
and reduced ICU stay. Late PN also shortened hospital
stay without affecting functionality at hospital discharge.
A formal cost-effectiveness analysis was a preplanned
substudy of the EPaNIC clinical trial [6]. As the EPaNIC
study did not show a benefit for the more expensive
nutritional strategy of Early PN, this preplanned analysis
was futile. Hence, we present a cost analysis from the
health-care payers’ perspective, exploring the magnitude
and the drivers of the cost difference that resulted from
the Early PN nutritional strategy [6].
Materials and methods
Preliminary comments
Within the context of the change in the plan, the fol-
lowing analyses were performed: First, we analyzed the
total health-care costs, dichotomized by the major clini-
cal outcomes of the study, in order to generate insight
into the relative contribution of patient outcomes to the
cost differences between both groups. These two major
clinical outcome variables were the acquisition of a new
infection and a prolonged ICU stay. Second, eight cost
categories, representing the different reimbursed services
and products during ICU and hospital stays, were stu-
died. The importance of each category to total hospitali-
zation costs and the influence of Early versus Late PN
were compared [7]. Third, the nature of the drugs
responsible for differences in pharmacy costs was inves-
tigated by using the Anatomical Therapeutic Chemical
(ATC) classification, the World Health Organization
(WHO) tool for drug utilization research. Finally, a
model was constructed to estimate the cost difference
between Early and Late PN if all PN purchase costs
would have been chargeable. Also, the total costs in the
ICU for vitamins and insulin - as crucial components of
the nutritional strategy - were described. The Institu-
tional Review Board of the University Hospitals of the
KU Leuven and of the Jessa Hospital approved the study
protocol, including the health economy analysis, and all
informed consent forms (ML4190).
Data collection
The cost study design took into account previously pub-
lished methodological guidelines [8-10]. For the con-
struction of the cost tree and for the examination of
cost categories, all direct health-care costs were calcu-
lated by using a bottom-up approach and were reported
in euros, rounded at zero decimals. The cost data were
not inflation-adjusted. During the trial, financial and
drug utilization data were collected and verified automa-
tically by the billing and warehousing collaborators
according to their standard operating procedures. These
collaborators were unaware of the ongoing trial. Upon
completion of the EPaNIC study, the data warehousing
collaborators were given only patient numbers, without
the randomization group. All costs were retrieved from
the individual patient invoices simultaneously for the
entire study population by using the data warehousing
system in the participating hospitals. These cost data
were stored and processed in FileMaker Pro 8.0 (File-
Maker Inc., Santa Clara, CA, USA). After data checks,
only the clinical investigators (SV, MPC, and DM) were
unblinded to treatment allocation.
No distinction was made between costs borne by the
health insurance and the individual patient co-payments.
Only direct health-care expenses, reflected by the offi-
cial, nationally fixed, tariffs were included. The perspec-
tive of the health-care payer is recommended in the
Belgian pharmaco-economic guidelines [11] and allows a
precise cost data analysis based on patient invoices.
Because the health-care payers’ perspective was taken,
the cost comparison of both arms of the study is inevi-
tably influenced by the particularities of the reimburse-
ment system in Belgian hospitals.
The relevant particularities for the study are the fol-
lowing:
• Medical services for which no fee can be charged
(either to the patient or the insurance company) are
not included in the invoice. Consequently, the costs
for these services were not accounted for in this cost
analysis.
• Some medical services (for example, clinical biol-
ogy), independently of whether they are provided to
the patient, are reimbursed largely through lump-
sum payments. These medical services are billed on
the invoice through per admission and per diem
(PD) fees.
• A number of pharmaceutical products, including
PN, are reimbursed in a ‘mixed system’: 25% of the
list price is reimbursed in addition to a lump-sum
reimbursement per hospital admission. Hence, only
25% of the PN cost is captured through the patient
invoice.
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• To cover the costs associated with the hospital stay
(nursing, support services, and care products other
than pharmaceutical products), Belgian hospitals
receive an annual budget. ‘Transfer’ of this budget to
the hospital is organized mainly (80%) through
monthly cash advances and, to a small extent (20%),
through a per admission and a PD fee. The levels of
these fees are identical for all patients in a specific
hospital. Hence, the ‘per diem hospitalization costs’
component of the patient invoice only partially
reflects the true resource use by ICU patients.
Because patients were recruited between August 2007
and November 2010, invoices are based on price rates
for four different years. During these four fiscal years,
the number of patients randomly assigned to one of the
two treatment groups did not differ. Since price fluctua-
tions of measured cost elements are relatively small, no
adjustment was made for the price variations during the
course of the clinical study.
The in-depth cost analysis involved all patients from
the original EPaNIC study, except 22 patients for whom
the sum of the invoice details was different from the
total amount invoiced. In order to avoid bias, these
patients were excluded from the analysis before unblind-
ing. As the study intervention took place only during
ICU stay but costs may be affected after ICU discharge,
the costs were examined in two periods. Period 1
extended from the day of ICU admission to the day of
discharge from the ICU. Period 2 covered costs from
after ICU discharge until the day of discharge from the
hospital (not shown in Tables 1 and 2). The time hori-
zon of this health economic evaluation was the entire
index stay (that is, the hospital where the patient was
initially included in the trial). Therefore, opportunity
costs and costs generated in hospitals or rehabilitation
centers, to which the patient was referred from the
index hospital, were not taken into account. Since the
time horizon was less than one year, neither costs nor
clinical effects were discounted. As the EPaNIC trial was
a priori powered only for clinical outcome variables and
the number of patients available for the cost analysis
was determined by the primary RCT, the statistical
power of the trial to detect the observed difference in
total costs was calculated a posteriori [12].
Cost tree
For further interpretation of the clinical effects in rela-
tion to costs, a cost tree was built [13,14]. As it was
unaffected by treatment allocation, hospital mortality
was not included in the cost tree. Therefore, the cost
tree was constructed on the treatment allocation (first
branch) and established excess cost-generating events
that were affected by the treatment allocation: new
Table 1 Healthcare costs split by major cost categories
Category Early PN, euros Late PN, euros Mean difference, euros P value
(t test)
Mean p25-p75 Mean p25-p75
Total hospital stay
Honoraria 7,058.00 4,762.00-7,126.00 6,812.00 4,732.00-7,037.00 246.00 0.16
Pharmacy 5,478.00 1,871.00-5,835.00 4,870.00 1,875.00-5,548.00 608.00 0.01
Hospitalization costs (PD) 2,221.00 654.00-1,950.00 2,126.00 653.00-1,849.00 95.00 0.63
Blood products 1,345.00 204.00-1,517.00 1,290.00 204.00-1,523.00 56.00 0.43
Clinical chemistry 963.00 253.00-1,141.00 889.00 255.00-1,035.00 75.00 0.05
Radiology 550.00 167.00-665.00 519.00 1,688.00-625.00 30.00 0.11
Miscellaneous 184.00 0.00-105.00 178.00 0.00-124.00 7.00 0.60
Graft products 165.00 0.00-0.00 167.00 0.00-0.00 −1.00 0.96
Total 17,965.00 8,746.00-18,661.00 16,851.00 8,788.00-17,749.00 1,114.00 0.04
Period 1 (ICU)
Honoraria 5,969.00 4,198.00-6,132.00 5,783.00 4,113.00-6,140.00 186.00 0.19
Pharmacy 4,679.00 1,754.00-5,210.00 4,231.00 1,737.00-5,175.00 448.00 0.04
Hospitalization costs (PD) 1,002.00 173.00-923.00 960.00 177.00-854.00 42.00 0.68
Blood products 1,216.00 167.00-1,351.00 1,125.00 166.00-1,383.00 91.00 0.17
Clinical chemistry 730.00 194.00-816.00 664.00 201.00-728.00 66.00 0.03
Radiology 332.00 61.00-400.00 310.00 64.00-338.00 23.00 0.12
Miscellaneous 52.00 0.00-0.00 51.00 0.00-0.00 1.00 0.86
Graft products 145.00 0.00-0.00 156.00 0.00-0.00 −11.00 0.73
Total 14,124.00 7,240.00-14,821.00 13,280.00 7,173.00-14,210.00 844.00 0.05
Early PN, parenteral nutrition administered during the first week of critical illness when enteral nutrition is insufficient; ICU, intensive care unit; Late PN, no
parenteral nutrition administered before day 8 of critical illness; p25-p75, interquartile range (25th and 75th percentiles); PD, per diem.
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infection [15,16] (second branch) and prolonged critical
illness as defined by an ICU stay beyond 8 days [17]
(third branch). The acquisition of a new infection and
ICU stay beyond 8 days were thus chosen as branches
because they were the principal acute clinical findings of
the EPaNIC trial [1]. For each branch, the proportion of
the total patient population meeting the branches’ clini-
cal criteria, the total health-care costs, and the mean
total health-care costs per patient were reported.
Examination of cost categories
So that the origin of the total cost difference between
Early and Late PN could be clarified comprehensively, a
second export for the detailed costs of all 4,640 patients
was done. These costs were allocated to one of eight
categories, a common classification used for hospital
invoices in Belgium: PD hospitalization costs, honoraria
for medical and allied health-care services, pharmacy
costs, blood products, clinical chemistry, radiology, graft
products, and a miscellaneous category [7]. However,
during a check of the blinded exports for total hospitali-
zation costs and the detailed export of costs per cate-
gory, inconsistency was detected in 22 patients. So that
bias could be avoided, this 0.47% of patients was deleted
from the detailed analyses and so data retrieval did not
need to be requested at the single patient level. The
Table 2 Pharmacie costs split by Anatomical Therapeutic Chemical classification system classes
Category Early PN, euros Late PN, euros Mean difference, euros P value (t test)
Mean p25-p75 Mean p25-p75
Total hospital stay
0 618.00 1.00-239.00 585.00 1.00-207.00 34.00 0.71
A 134.00 25.00-146.00 124.00 24.00-126.00 9.00 0.14
B 1,162.00 202.00-1,102.00 942.00 176.00-830.00 220.00 0.006
C 137.00 16.00-119.00 133.00 16.00-109.00 5.00 0.61
D 23.00 0.00-13.00 17.00 0.00-12.00 6.00 0.12
G 3.00 0.00-0.00 7.00 0.00-0.00 −4.00 0.08
H 94.00 0.00-15.00 80.00 0.00-11.00 14.00 0.50
J 1,117.00 17.00-739.00 889.00 17.00-649.00 227.00 0.02
L 187.00 0.00-0.00 161.00 0.00-0.00 26.00 0.23
M 27.00 0.00-16.00 20.00 0.00-15.00 7.00 0.05
N 260.00 56.00-215.00 240.00 54.00-202.00 20.00 0.34
P 0.00 0.00-0.00 0.00 0.00-0.00 0.00 0.17
R 17.00 0.00-16.00 16.00 0.00-16.00 1.00 0.42
S 2.00 0.00-0.00 1.00 0.00-0.00 0.00 0.14
V 59.00 2.00-40.00 51.00 3.00-32.00 8.00 0.13
Total 3,843.00 414.00-3,866.00 3,271.00 397.00-3,314.00 572.00 0.01
Period 1 (in ICU)
0 330.00 0.00-91.00 370.00 0.00-69.00 −40.00 0.60
A 90.00 16.00-92.00 82.00 14.00-74.00 8.00 0.11
B 797.00 133.00-718.00 612.00 101.00-467.00 186.00 0.0001
C 110.00 5.00-92.00 102.00 5.00-77.00 8.00 0.34
D 13.00 0.00-6.00 8.00 0.00-4.00 5.00 0.13
G 2.00 0.00-0.00 2.00 0.00-0.00 0.00 0.56
H 45.00 0.00-7.00 35.00 0.00-4.00 10.00 0.17
J 665.00 9.00-317.00 520.00 9.00-221.00 145.00 0.04
L 115.00 0.00-0.00 99.00 0.00-0.00 16.00 0.29
M 18.00 0.00-9.00 15.00 0.00-8.00 4.00 0.08
N 200.00 35.00-154.00 184.00 33.00-138.00 16.00 0.36
P 0.00 0.00-0.00 0.00 0.00-0.00 0.00 0.71
R 7.00 0.00-4.00 6.00 0.00-3.00 1.00 0.48
S 1.00 0.00-0.00 1.00 0.00-0.00 0.00 0.46
V 38.00 2.00-15.00 31.00 2.00-12.00 6.00 0.15
Total 2,435.00 252.00-2,005.00 2,071.00 235.00-1,458.00 364.00 0.03
Early PN, parenteral nutrition administered during the first week of critical illness when enteral nutrition is insufficient; ICU, intensive care unit; Late PN, no
parenteral nutrition administered before day 8 of critical illness; p25-p75, interquartile range (25th and 75th percentiles).
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different cost categories were reported for periods 1 and
2 (not shown in Tables 1 and 2) separately and were
aggregated. A Pareto chart visualized the contribution of
each category to total health-care costs [18]. Cost dri-
vers were defined as the combination of the largest cost
categories that explained at least 80% of the total
health-care costs in the Early-PN group. For these eight
categories, cost differences between both study arms
during both periods were assessed.
Drug costs
So that the nature of the drugs responsible for cost dif-
ferences between Early and Late PN could be identified,
drug costs were analyzed by using the ATC classifica-
tion system, the tool for presenting drug utilization sta-
tistics from the WHO [19] (Table 3). Drugs are
classified in groups at five different levels. The drugs are
divided into 14 main groups (first, or ‘anatomical’, level)
and into pharmacological/therapeutic subgroups (second
level). The third and fourth levels are chemical/pharma-
cological/therapeutic subgroups, and the fifth level is the
chemical substance. The billed units for each drug (level
5 of the ATC classification) were retrieved from the
data warehousing system from the pharmacies of the
participating hospitals. The model, estimating the drug
costs for every ATC class, used the official list prices of
2011. The total pharmacy costs mentioned previously
were the sum of drug costs billed in their respective fis-
cal year. Devices or appliances accounted for in the data
warehousing system, but not ATC-classified (for exam-
ple, disposables, drains, and wound dressings), were
grouped under the ATC-0 code. So that the highest
accuracy could be provided, insulin costs were based on
units administered per patient during ICU stay as
recorded in the clinical research file.
Cost evaluation and sensitivity analysis
In the Belgian health-care system, the patients’ invoices
charge only 25% of PN purchase costs and thus una-
voidably underestimate the cost of Early PN in the ICU.
Therefore, in the sensitivity analysis, the impact of PN
on the total incremental health care costs was calculated
as if all PN purchase costs were chargeable to the
health-care payer. We therefore added 75% of the mean
costs during ICU stay in ATC subcategory level 4
B05BA (PN) to the total mean incremental health-care
costs obtained from the patient invoices.
Statistical analysis
All costs are presented as the mean and the interquartile
range (25th and 75th percentiles). The costs in the two
treatment groups were analyzed with the Student t test,
and the costs between periods 1 and 2 were analyzed
with the paired t test [12,20]. P values of 0.05 or lower
were deemed significant. Analyses were performed with
JMP (version 8.0.1) (SAS Institute Inc., Cary, NC, USA).
All analyses were performed on an intention-to-treat
basis.
Results
Summary of clinical results and total health-care costs
As previously reported, Late PN prevented new infec-
tions in the ICU and enhanced organ function recovery.
Moreover, Late PN, in comparison with Early PN, shor-
tened ICU and hospital stays and reduced mean total
incremental health-care costs by €1,110.00 [3]. Calcula-
tion (with a one-tail test using an alpha level of 5%) of
the statistical power of the observed overall difference in
total incremental costs - Early PN (n = 2,312, mean cost
of €17,973.00, standard deviation (SD) of €18,965.00)
and Late PN (n = 2,328, mean cost of €16,863.00, SD of
€18,190.00) - yielded a value of 65.2% [21].
Cost tree
Only 24.5% of the patients acquired a new infection in
the ICU but accounted for 42.7% of the total costs dur-
ing the EPaNIC study (Figure 1). Likewise, patients with
a prolonged ICU stay accounted for 43.3% of the total
costs but represented only 24.2% of the entire popula-
tion. Late PN reduced mean total costs per patient in all
branches of the tree. In the clinically strived for patient
population (70.1% of the total population), namely
patients who do not develop a new infection and who
do not require prolonged ICU support, the cost increase
by Early PN was only €94.00 per patient. In contrast, in
patients who had a prolonged ICU stay without a new
Table 3 Anatomical Therapeutic Chemical classification
system: level 1
Code Contents
A Alimentary tract and metabolism
B Blood and blood-forming organs
C Cardiovascular system
D Dermatologicals
G Genito-urinary system and sex hormones
H Systemic hormonal preparations, excluding sex hormones and
insulins
J Anti-infectives for systemic use
L Antineoplastic and immunomodulating agents
M Musculo-skeletal system
N Nervous system
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infection, the mean cost increase by Early PN was
€2,917.00.
Examination of cost categories
For the total hospital stay, honoraria, pharmacy, and PD
hospitalization costs represented 82.1% of the total costs
(Figure 2 and Table 1). For period 1 (ICU), honoraria,
pharmacy, and blood products represented 84.0% of the
total costs; 80.9% of the total costs in period 2 (after
ICU) were driven by PD hospitalization costs, honoraria,
and pharmacy costs (data not shown).
The overall increased cost for the Early-PN group was
brought about by higher costs for pharmacy and for
clinical chemistry. Those cost differences were
Figure 1 Cost tree (cost allocation in the form of a decision tree). Costs are allocated by studied randomly assigned treatment (first branch),
by the acquisition of a new infection (second branch), and by prolonged intensive care unit (ICU) stay, defined as an ICU stay beyond 8 days
(third branch). The percentages represent the proportion of patients for the entire study population in each branch. The costs in euros (EUR)
represent the total costs for all patients in each branch and - between brackets - mean cost per patient. Costs reported in euros are rounded at
zero decimals. Early PN, parenteral nutrition administered during the first week of critical illness when enteral nutrition is insufficient; Late PN, no
parenteral nutrition administered before day 8 of critical illness.
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significantly present only in period 1, which was respon-
sible for 79% of the total hospital stay costs. The
increased pharmacy costs with Early PN (mean differ-
ence + €608.00 per patient, P = 0.01) explained 54.6% of
the mean total difference in costs between the two ran-
domization groups (+ €1,114.00 per patient).
Drug costs
The difference in pharmacy costs was explained predo-
minantly by the fact that Early PN increased expenses in
the ATC level 1 categories B (blood products and perfu-
sion fluids) and J (anti-infective agents for systemic use)
and by a smaller difference in category M (musculo-ske-
letal system) (Table 2). Costs for drug utilization in the
ICU represented 63.6% of the total drug costs. Total
costs in ATC subcategory B05BA ‘Parenteral nutrition’
(level 4) during ICU stay were €610,584.00 in the Early-
PN group (mean of €266.00 per patient) and
€317,275.00 in the Late-PN group (mean of €137.00 per
patient); the mean difference was €129.00 per patient (P
<0.0001). The largest proportions of these PN costs
were covered by combined PN bags (B05BA10: 88.7% in
the Early-PN group and 80.4% in the Late-PN group)
followed by carbohydrate solutions (B05BA03: 8.9% in
the Early-PN group and 16.1% in the Late-PN group).
The costs for separate protein (B05BA01) or lipid solu-
tions (B05BA02) were negligible in both groups.
Total costs for vitamins were €65,162.00 (mean of
€28.00 per patient) and €49,981.00 (€21.00 per patient)
in the Early- and the Late-PN group, respectively. Total
costs for insulin, based on units administered per
patient, were €32,230.00 (mean of €14.00 per patient) in
the Early-PN group and €20,392.00 (mean of €9.00 per
patient) in the Late-PN group.
Aggregated costs of ATC level 2 subcategories J01
‘Antibacterials for systemic use’ and J02 ‘Antimycotics
for systemic use’ during ICU stay were €1,363,396.00 in
the Early-PN group (mean of €593.00 per patient) and
€1,026,189.00 in the Late-PN group (mean of €443.00
per patient); the mean difference was €150.00 per
patient (P = 0.26). Class B and J drugs together repre-
sented 59.3% of the total pharmacy costs in the Early-
PN group and 56.0% in the Late-PN group.
Cost evaluation and sensitivity analysis
Adding 75% (not billable fraction) of the PN purchase
costs obtained from the pharmacy warehouse (ATC
B05BA) for period 1 to the total costs in both groups
Figure 2 Pareto chart of the costs for the total EPaNIC trial population. The histogram depicts the relative size of each cost category in
comparison with the total cost. The line graph shows their cumulative contribution. Important cost drivers for total hospital stay in the EPaNIC
trial population are highlighted. EPaNIC, Impact of Early Parenteral Nutrition completing enteral nutrition In Critical illness; PD, per diem.
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resulted in mean total costs of €18,173.00 [(€266.00 ×
0.75) + €17,973.00] in the Early-PN group and
€16,963.00 [(€137.00 × 0.75) + €16,863.00] in the Late-
PN group, increasing the mean difference to €1,210.00
per patient (P = 0.02).
Discussion
A large Belgian multicenter RCT showed that Late PN
prevented infections and enhanced recovery in a mixed
population of critically ill patients [3]. Moreover, Late
PN resulted in lower total billed costs during hospital
stay. As Early PN did not demonstrate a clinical benefit
and is more expensive, a formal cost-effectiveness analy-
sis was superfluous. Therefore, in this health economy
analysis, we sought to further investigate this mean cost
increase of €1,110.00 per patient by Early PN. The cost-
tree analysis confirmed existing literature that the devel-
opment of new infections and prolonged ICU stay have
a major impact on acute health-care costs for critically
ill patients [15,17]. Patients who contracted a new infec-
tion in the ICU or had to stay in the ICU beyond 8 days
each represented a quarter of the ICU population but
almost half of the costs.
Early PN consistently increased mean health-care
costs per patient in all patient subpopulations. Honor-
aria, pharmacy costs, and PD hospitalization cost cate-
gories represented over 80% of the total hospital stay
costs. During ICU stay, costs for blood products also
contributed importantly to total costs. This is in line
with a recent micro-costing study in which the require-
ment for expensive interventions, comprising blood pro-
ducts, antifungals, and hemofiltration, was the main
driver for ICU costs [7]. In the ICU, Early PN increased
costs for the large pharmacy cost category and for clini-
cal chemistry. The lower proportion of costs and the
considerable individual cost variation resulted in a
blunted effect of Late PN after ICU discharge. The
higher pharmacy costs in the Early-PN group accounted
for over 50% of the cost increase. Not only the cost for
ATC class B (drugs for blood and blood forming organs)
-which includes PN- but also the costs for ATC class J
medication (systemic antibacterial and antimycotic
agents) were higher. The higher costs for antibiotics and
antimyotics corroborate the finding from the clinical
study that Early PN increased the incidence of new
infections.
More prescription of combined PN bags was the sin-
gle most important contributor to the costs for PN. The
costs for vitamins and insulin, generally regarded as part
of the nutritional strategy, were much lower. Pharmacy
costs obtained from the accounting department were
higher than the costs for drugs retrieved from the phar-
macy data warehousing system. The costs for prepara-
tion of drugs and their delivery may have contributed to
this difference. In addition, the costs for non-ATC-clas-
sified pharmacy products, such as disposables, were not
entirely covered in the pharmacy data warehousing sys-
tem. Moreover, the latter model used 2011 prices for all
patients whereas the accounting department provided
true costs per fiscal year. The sensitivity analysis making
total incremental health-care costs comparable with
other health-care systems that fully charge PN revealed
a mean €1,210.00 cost difference per patient, benefiting
Late PN.
From the EPaNIC RCT it can be concluded that the
nutritional strategy of Early PN was inferior to Late PN
in adult critically ill patients. Early PN was less effective
(605 versus 531 patients with a new ICU infection and
prolonged duration of organ replacing therapy and of
ICU and hospital dependency) and more expensive
(€610,584.00 versus €317,275.00) than Late PN.
In light of the lack of clearly demonstrated benefits of
PN, clinicians considering its early administration
should realize that, besides the purchase cost of PN
itself, this strategy will, above all, generate important
expenses mediated by clinical complications. The benefit
of Late PN, from clinical and cost perspectives, places
the practice of withholding PN until day 8 in the ICU in
the southeast quadrant of the cost-effectiveness plane
[14]. Rarely, intervention studies in hospitalized patients
bring forward strategies that are less costly and at the
same time more effective than standard practice. The
strategy of blood glucose control with intensive insulin
therapy, which reduces morbidity and mortality in surgi-
cal critically ill patients and has a low technology cost of
€72.00 per patient, also resulted in a large cost saving of
€2,638.00 per patient [22]. Other studies in a broad
spectrum of critically ill patients confirmed these eco-
nomic benefits [23,24]. In contrast, strategies depending
on newly developed drugs are usually more costly. A
notable example is the use of activated protein C (dotre-
cogin alpha), which appeared to be effective only in
patients with very severe sepsis but which costs US
$160,000.00 per life saved [25,26].
This health economic analysis of the EPaNIC trial has
some shortcomings that should be highlighted [27]. As
the economic evaluation is trial-based, the occurrence of
a protocol-driven resource use cannot be excluded and
this could reduce generalizability. The micro-costing
approach may have further amplified this lack of gener-
alizability but contributed to the validity of cost esti-
mates. Also, although the EPaNIC trial was adequately
powered for the clinical outcomes, its statistical power
to detect differences in total costs was somewhat weaker
because of the substantial variability in total costs per
patient. Lastly, the economic evaluation was set in the
Belgian health-care system. Hence, cost impact of Early
PN cannot be generalized as such to other health-care
Vanderheyden et al. Critical Care 2012, 16:R96
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systems. Although the actual cost savings will differ
from hospital to hospital and from country to country,
the beneficial cost effect of Late PN is likely to be con-
firmed as long as the clinical data are confirmed in
other settings.
Conclusions
This health economy analysis based on accounting
department and pharmacy warehouse data provides
external validation of the clinical results of the EPaNIC
trial. It is clear that the practice of Early PN in critically
ill patients cannot be recommended as it did not show
benefit and it increased health-care costs.
Key messages
• Early parenteral nutrition (PN) increased total
health-care costs by increasing pharmacy-related
costs, which represent 30% of the total costs from a
health-care payer’s perspective.
• Early PN increased pharmacy-related costs not
only by PN purchase costs but also by high increases
in the costs for anti-infective agents.
• This health economy analysis based on accounting
department and pharmacy warehouse data provided
external validation of the clinical results of the EPa-
NIC trial.
• For clinical and for health economic reasons, early
PN in critically ill patients cannot be recommended.
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